Last reviewed · How we verify
ST266 delayed
At a glance
| Generic name | ST266 delayed |
|---|---|
| Sponsor | Noveome Biotherapeutics, formerly Stemnion |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ST266 in UV-induced Inflammation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ST266 delayed CI brief — competitive landscape report
- ST266 delayed updates RSS · CI watch RSS
- Noveome Biotherapeutics, formerly Stemnion portfolio CI